Editorial: Covid-19 therapies in patients with hematologic malignancies.

Publication date: Feb 05, 2024

Open Access PDF

Concepts Keywords
Covid COVID
Hematologic hematologic malignancies
Malignancies rituximab
Therapies tixagevimab/cilgavimab
vaccine

Semantics

Type Source Name
disease MESH Covid-19
disease MESH hematologic malignancies
pathway REACTOME Reproduction
disease VO vaccine
disease MESH long COVID
disease MESH chronic lymphocytic leukemia
disease MESH multiple myeloma
disease MESH infection
disease MESH complications
disease MESH death
disease MESH malignancies
disease VO vaccination
disease VO population
disease VO effectiveness
disease VO dose
drug DRUGBANK Lenalidomide
drug DRUGBANK Ibrutinib
drug DRUGBANK Venetoclax
disease IDO cell
pathway KEGG Proteasome
disease VO vaccinated
disease MESH non Hodgkin lymphoma
drug DRUGBANK Rituximab
disease VO titer
disease MESH myelofibrosis
disease MESH polycythemia vera
drug DRUGBANK Ruxolitinib
disease VO antibody titer
disease MESH acute lymphoblastic leukemia
drug DRUGBANK Isoxaflutole
disease IDO process
drug DRUGBANK Etodolac
disease MESH bleeding

Original Article

(Visited 2 times, 1 visits today)